Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01274637 · ClinicalTrials.gov registry record · Phase 3
PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
A Phase 3 study, sponsored by Ottawa Hospital Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT01274637: Completed Phase 3 study, sponsored by Ottawa Hospital Research Institute.
NCT01274637 is a Phase 3 study that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 62 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01274637, a Phase 3 study, has completed, sponsored by Ottawa Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if it is feasible to conduct a multi-center randomized trial to determine whether a blood thinner, low-molecular-weight-heparin (LMWH), is effective at preventing blood clots, thromboembolism (VTE), in postpartum women at risk.
Primary Outcome
The average number of subjects that are recruited per site per month during a 4 month active recruitment phase at each site.
Interventions
- DRUG Dalteparin Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
What the finished NCT01274637 record still lists
NCT01274637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Dalteparin Sodium is the first listed.
NCT01274637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01274637 about?
NCT01274637 is a clinical study titled "PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot". The purpose of this study is to determine if it is feasible to conduct a multi-center randomized trial to determine whether a blood thinner, low-molecular-weight-heparin (LMWH), is effective at preventing blood clots, thromboembolism (VTE), in postpartum women at risk.
What is the current status of trial NCT01274637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2011-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01274637?
The interventions under investigation include: Dalteparin Sodium (DRUG).
Who is sponsoring clinical trial NCT01274637?
This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01274637's enrollment target sits among peer trials
62 1802nd of 2000 higher than 198 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia